HKSTP Deepens Partnership with Roche to Propel MedTech Startups to Global Stage
SingTao · 2 SOURCESabout 3 hours ago2 MIN
Summary
Hong Kong Science and Technology Parks Corporation (HKSTP) has formally signed a strategic cooperation agreement with international healthcare company Roche, deepening collaboration in medical technology and biomedical innovation. The partnership upgrades support from early-stage research and startup incubation to full end-to-end transformation and commercialization assistance, aiming to accelerate local research outcomes toward clinical application and global markets, further solidifying Hong Kong's position as an international medical innovation hub.
Key Points
- HKSTP and Roche formalized the strategic agreement on October 15, 2026, expanding their partnership that began in 2023
- The collaboration introduces AI medical technologies to enhance early screening and health management for cancer and chronic diseases
- Roche brings extensive clinical trial experience, having conducted approximately 140 clinical studies in Hong Kong over recent years and currently running about 25 studies
- Joint startup competitions will identify high-potential life science projects, combining HKSTP's Incu-Bio program with Roche's global network
- HKSTP Life Sciences Technology Director Tse Lai Kuen stated that Roche's market insights and global network can help startups accelerate clinical validation
- Roche is collaborating with universities on AI fundus examination technology to detect early age-related macular degeneration
- Roche Diagnostics Hong Kong General Manager Law Tsz Yin highlighted that aging populations require a shift toward proactive prevention
Why It Matters
This deepened partnership directly addresses Hong Kong's aging population and rising chronic disease burden by bringing world-class clinical trial infrastructure and AI diagnostic capabilities to local startups, potentially reducing the time and cost for innovative medical products to reach patients while positioning Hong Kong as a regional clinical research center.
This deepened partnership directly addresses Hong Kong's aging population and rising chronic disease burden by bringing world-class clinical trial infrastructure and AI diagnostic capabilities to local startups, potentially reducing the time and cost for innovative medical products to reach patients while positioning Hong Kong as a regional clinical research center.